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Abstract
Background: Chronic inflammation is a key player in pathogenesis. The inflammatory cytokine, tumor necrosis factor-
alpha is a well known inflammatory protein, and has been a therapeutic target for the treatment of diseases such as
Rheumatoid Arthritis and Crohn's Disease. Obesity is a well known risk factor for developing non-insulin dependent
diabetes melitus. Adipose tissue has been shown to produce tumor necrosis factor-alpha, which has the ability to reduce
insulin secretion and induce insulin resistance. Based on these observations, we sought to investigate the impact of
unsaturated fatty acids such as oleic acid in the presence of TNF-α in terms of insulin production, the molecular
mechanisms involved and the in vivo effect of a diet high in oleic acid on a mouse model of type II diabetes, KKAy.
Methods: The rat pancreatic beta cell line INS-1 was used as a cell biological model since it exhibits glucose dependent
insulin secretion. Insulin production assessment was carried out using enzyme linked immunosorbent assay and cAMP
quantification with competitive ELISA. Viability of TNF-α and oleic acid treated cells was evaluated using flow cytometry.
PPAR-γ translocation was assessed using a PPRE based ELISA system. In vivo studies were carried out on adult male KKAy
mice and glucose levels were measured with a glucometer.
Results: Oleic acid and peanut oil high in oleic acid were able to enhance insulin production in INS-1. TNF-α inhibited
insulin production but pre-treatment with oleic acid reversed this inhibitory effect. The viability status of INS-1 cells
treated with TNF-α and oleic acid was not affected. Translocation of the peroxisome proliferator- activated receptor
transcription factor to the nucleus was elevated in oleic acid treated cells. Finally, type II diabetic mice that were
administered a high oleic acid diet derived from peanut oil, had decreased glucose levels compared to animals
administered a high fat diet with no oleic acid.
Conclusion:  Oleic acid was found to be effective in reversing the inhibitory effect in insulin production of the
inflammatory cytokine TNF-α. This finding is consistent with the reported therapeutic characteristics of other
monounsaturated and polyunsaturated fatty acids. Furthermore, a diet high in oleic acid, which can be easily achieved
through consumption of peanuts and olive oil, can have a beneficial effect in type II diabetes and ultimately reverse the
negative effects of inflammatory cytokines observed in obesity and non insulin dependent diabetes mellitus.
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Background
Acute inflammation is utilized by the immune system to
effectively isolate and eliminate pathogenic microorgan-
isms. Among the most commonly observed cytokines in
inflammatory microenvironments is Tumor Necrosis Fac-
tor-alpha (TNF-α) [1]. This cytokine is produced by a vari-
ety of immune cells and is pleiotropic in nature[2]. TNF-
α is also produced by adipose tissue and it is thought to
play a major role in the Metabolic Syndrome (MS), which
is characterized by insulin resistance and inflamma-
tion[3]. Studies utilizing the INS-1 glucose dependent
insulin secreting cell line, have shown that TNF-α is capa-
ble of inhibiting insulin secretion[4,5]. Furthermore,
TNF-α interferes with insulin signalling in a variety of
non-insulin producing cells, essentially inducing a state of
insulin resistance[6]. The concept of chronic low level
inflammation playing an important role in a number of
diseases is beginning to gain acceptance in the medical
community. The anti-inflammatory properties of choles-
terol lowering drugs, collectively referred to as statins, is
an excellent example that provides support for this con-
cept. The anti-inflammatory therapeutic effect of statins
on individuals that have normal cholesterol, but have ele-
vated high sensitivity C-reactive protein (hsCRP), an
inflammatory marker, was shown in the recently com-
pleted Jupiter study[7]. This finding is strongly indicative
of the importance of regulating inflammation and ulti-
mately avoiding disease in the future.
Polyunsaturated Fatty Acids (PUFAs) and Monounsatu-
rated Fatty Acids (MUFAs) have received a lot of attention
in the last decade and their health benefits are becoming
increasingly evident [8-10]. Due to the widespread practice
of hydrogenation in processed foods, the levels of saturated
fatty acids being consumed by populations residing in
developed countries has increased significantly and the
subsequent increase in cardiovascular disease and meta-
bolic disorders is becoming a significant public health issue
[11]. The specific mechanisms through which unsaturated
fatty acids exert their therapeutic properties are quite varied.
Metabolites of Eicosapentaenoic Acid (EPA) and Docosa-
hexaenoic Acid (DHA) collectively referred to as Resolvins,
have been shown to be potent anti-inflammatory
agents[12,13]. A number of unsaturated fatty acids have
also been shown to bind the Peroxisome Proliferator-Acti-
vated Receptor-gamma (PPAR-γ)[14]. The binding of free
fatty acids to PPAR-γ has been shown to result in the trans-
location of the receptor to the nucleus and regulation of
gene expression. Contrary to PUFAs and MUFAs, saturated
fatty acids are associated with inflammation at the level of
adipose tissue[15]. Mediterranean populations with dietary
habits that are high in MUFAs, partly due to high olive oil
consumption, have considerably reduced inflammatory
markers when compared to populations that have lower
oleic acid intake [16-18].
In this study, we show that oleic acid and peanut oil high
in oleic acid can reverse the inhibitory effect of the inflam-
matory cytokine TNF-α on insulin production both in
vitro and in vivo. Furthermore, a peanut oil diet high in
oleic acid can reverse hyperglycemia in a mouse model of
type II diabetes. These findings further support the use of
diet manipulation to treat diseases that have an inflam-
matory aetiology.
Methods
Cell cultures
The glucose sensitive rat pancreatic β-cell line INS-1, was
kindly provided by Dr. Karl Olson at Michigan State Uni-
versity. The cells were grown in RPMI 1640 medium (Inv-
itrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, 1% streptomycin, gen-
tamycin, amphotericin B antibiotic/antimycotic). Cells
were grown at 37°C and 5% CO2 atmosphere. 25 cm2 tis-
sue culture treated flasks were used for cell expansion.
Upon 80% confluence, cells were detached with trypsin
and sub-cultured.
Oil extractions and analysis
"NOP" oil ("HAIN" brand produced by The Hain Celestial
group, Inc, Garden City, NY, USA) and two "HOP" oils
("USDA" kindly provided by United States Department of
Agriculture, and "GOLD" produced by Golden Peanut
Company, Alpharetta, GA, USA) were used. One mL of
both "HOP" oils were extracted twice with chloroform:
methanol (1:1; v/v), 95% ethanol and ethanol: ether (2:3;
v/v) separately. Extracts were evaporated to dryness under
nitrogen and solubilised in 1.0 mL of 5% dimethyl sulfox-
ide, DMSO, in phosphate buffered saline, PBS.
Fatty acid composition of oils was carried out by J. Leek
Associates, Inc. Albany, GA, USA.
Insulin assay
Secreted insulin was measured using 25 μL of diluted
(×10) supernatant from each well (100,000 cells/mL; 200
μL) of 96 well plates using Insulin (Rat) Ultra Sensitive
EIA kit from ALPCO diagnostics (Windham, NM, USA).
In brief, 25 μl standard, control and unknown were incu-
bated separately with 75 μL conjugate solution, contain-
ing insulin antibody, for 120 min at room temperature on
a microplate rotator shaking approximately at 800 rpm.
Plates were washed 6 times manually and allowed to react
with 3, 3', 5, 5'-tetramethylbenzidine peroxidase substrate
for at least 15 min at room temperature. Reactions were
stopped by addition of 50 μL stop solution. Finally, bi-
chromatic absorbance measurement with reference at 650
and 450 nm were performed using a Benchmark Biorad
Microplate spectrophotometric reader (BioRad, Sunny-
ville, CA, USA). Values were expressed either as (mean ±
SEM or SD) pg/mL of insulin.Lipids in Health and Disease 2009, 8:25 http://www.lipidworld.com/content/8/1/25
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cAMP assay
cAMP intracellular levels of INS-1 cells were determined
using a cAMP Assay Kit obtained from Cayman Chemicals
(Ann Arbor, MI, USA) according to manufacturer's
instructions. Briefly, INS-1 cells were seeded (2 × 105 cells/
mL) in a 96- well plate in 200 μL medium for 24 hrs and
treated with oleic acid at various concentrations for 15
min. Supernatant was removed followed by addition of
100 μL of 0.1 M HCl and 20 minute incubation for cell
lysis. Cells were then removed with a rubber policeman,
homogenized by repetitive pippetting and centrifuged at
1,000 g. Supernatants were then transferred to a new tube
and cAMP levels were measured.
PPAR-  binding to PPRE containing oligonucleotides
PPAR-γ binding to peroxisome proliferator responsive ele-
ment (PPRE) containing oligonucleotides was assayed by
measuring binding of nuclear extract homogenates to a spe-
cific double stranded DNA oligonucleotide sequence immo-
bilized on a 96 well plate that contains the PPRE. PPAR-γ was
detected using a specific primary antibody followed by a sec-
ondary antibody conjugated to HRP and colorimetric read-
out at 450 nm. Nuclear extract preparation was carried out as
per manufacturer's instructions (Cayman Chemicals). 3 ×
106 cells were used for each treatment and a total of 2 μg
nuclear extract was incubated in each well overnight at 4°C
without agitation. Detection antibodies and positive con-
trols were provided with the manufacturer's kit.
Apoptosis assay
Annexin V/propidium iodide (PI) staining of INS-1 cells
cultured with TNF-α and oleic acid at varied concentra-
tions for 24 hrs were washed and adjusted to 1 × 106 cells/
mL in staining buffer. Staining was performed as recom-
mended by BD Pharmingen (San Diego, CA, USA). Cells
were analyzed immediately by flow cytometry. Annexin V
has high affinity for phosphatidylserine that is translo-
cated to the outer leaflet of the plasma membrane during
apoptosis. PI intercalates in the DNA of apoptotic cells
with compromised plasma membrane.
In vivo studies
Adult male Kunming (10–12 week old) and KKAy mice
(8–10 week old) were supplied by the Institute of Phar-
macology, Chinese Academy of Medical Sciences. Mice
were given food (different diets according to the need of
the experiment) and water ad libitum. The animals were
kept in a pathogen free environment for a 12-h light, 12-
h dark cycle. All animal experiments were conducted
according to the guidelines of the local animal use and
care committee and executed according to the National
Animal Law.
KKAy mice were divided into three groups: a control group
(C, kept on normal diet), a Type 2 diabetes group (DM2,
kept on a high fat diet), and a peanut oil treated DM2
group (DM2 + peanut oil) kept on a high fat diet. After 7
days of high fat diet when the blood glucose was higher
than 15 mM, the mice were administered 0.70 mL/day,
~2.0–2.5% w/w, of peanut oil by gavage for 21 days. On a
calorie basis, the high fat diet consisted of 58% fat
whereas the normal diet contained 11.4% fat[19].
Statistics
Statistical significance was established using standard
paired student t-test using Sigmaplot® or Microsoft Excel®
software.
Results
Oleic acid enhances insulin production and reverses the 
inhibitory effect of TNF-  in INS-1 cells
MUFAs have been shown to exert pleiotropic effects on a
variety of cell types. Of particular interest to the scientific
community focusing on inflammation, is their ability to
modulate insulin production. With this perspective in
mind and preliminary findings previously reported, we
first assessed the effect of oleic acid on insulin production
by the glucose dependent insulin producing rat pancreatic
cell line, INS-1[20]. We observed a significant increase in
insulin production by INS-1 cells grown in medium con-
taining 11 mM glucose and treated with oleic acid at 10
μM and 5 μM (Fig. 1A). Significant increase in insulin pro-
duction was observed by INS-1 cells grown in medium
containing 25 mM glucose and treated with oleic acid at
10 μM and 5 μM (Fig. 1B).
The inflammatory cytokine TNF-α is known to inhibit
insulin secretion[5]. Inflammatory cytokines have also
been reported to be elevated in both obese individuals
and obese individuals that are type II diabetic[21]. Fur-
thermore, obesity and inflammation are considered
major risk factors in type II diabetes and hyperten-
sion[22]. Besides type II diabetes, chronic inflammation
which increases with age, is considered to be a major risk
factor for cardiovascular disease[23]. Taking into consid-
eration these findings, we sought to investigate the impact
of oleic acid in a simulated inflammatory environment
using TNF-α. Oleic acid at 10 μM and 5 μM was able to
reverse the inhibitory effect of TNF-α (100 pg/mL) (Fig.
2A). This finding shows that oleic acid is capable of revers-
ing the inhibitory effect of the inflammatory cytokine
TNF-α and reveals the potential therapeutic effect of oleic
acid and MUFAs in an inflammatory context. We observed
a similar effect of insulin production at high glucose (25
mM) culturing conditions with oleic acid treatments at 10
μM and 5 μM and TNF-α (100 pg/mL), (Fig. 2B). Interest-
ingly, these effects are observed after two hours pre-treat-
ment of the cells with oleic acid.
Effect of oleic acid and TNF-  on apoptosis of INS-1cells
INS-1 cells are susceptible to apoptosis and use of oleic
acid and TNF-α has the potential to induce apoptosis. Fur-Lipids in Health and Disease 2009, 8:25 http://www.lipidworld.com/content/8/1/25
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Insulin production by INS-1 cells treated oleic acid Figure 1
Insulin production by INS-1 cells treated oleic acid. (A) INS-1 cells were cultured (11 mM glucose) with varying concen-
trations of oleic acid for 18–24 hrs at 37°C. Shown is one representative experiment with triplicate values out of three inde-
pendent experiments. *, p < 0.05 for untreated cells compared to cells treated with 10 μM and 5 μM oleic acid. (B) INS-1 cells 
were cultured (25 mM glucose) with varying concentrations of oleic acid for 18–24 hrs at 37°C. Shown is one representative 
experiment with triplicate values out of three independent experiments. *, p < 0.05 for untreated cells compared to cells 
treated with 10 μM and 5 μM oleic acid.
Increased insulin production by INS-1 cells treated with TNF-α and oleic acid Figure 2
Increased insulin production by INS-1 cells treated with TNF-α and oleic acid. (A) INS-1 cells were pre-treated for 
two hours with varying concentrations of oleic acid in medium containing 11 mM glucose, followed by TNF-α (100 pg/mL) 
treatment for 18–24 hrs at 37°C. Shown is one representative experiment with triplicate values out of three independent 
experiments.*, p < 0.05 for cells treated with TNF-α compared to cells treated with TNF-α and 10 μM or 5 μM oleic acid. (B) 
Cells were pre-treated for two hours with varying concentrations of oleic acid in medium containing 25 mM glucose, followed 
by TNF-α (100 pg/mL) treatment for 18–24 hrs at 37°C. Shown is one representative experiment with triplicate values out of 
three independent experiments. *, p < 0.05 for cells treated with TNF-α compared to cells treated with TNF-α and 10 μM or 
5 μM oleic acid.Lipids in Health and Disease 2009, 8:25 http://www.lipidworld.com/content/8/1/25
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thermore, oleic acid could exert its insulinogenic effect by
inhibiting apoptosis. To address these possibilities, we
assessed the apoptotic status of INS-1 cells under the same
experimental conditions that we observed induction of
insulin secretion in the presence of oleic acid, as well as
reversal of insulin inhibition in the presence of oleic acid
and TNF-α. We specifically chose to utilize the annexin V/
PI assay primarily for its ability to detect early apoptosis
via exposure of phosphatidyl serine on the extracytoplas-
mic side of the plasma membrane. At 24 hours, we did not
observe any statistically significant increase in apoptosis
in the presence of high (1,000 pg/mL) or low (100 pg/
mL) TNF-α concentration (Fig. 3). We observed a small
statistically insignificant reduction in baseline apoptosis
in the presence of oleic acid in both high (10 μM) and low
(1 μM) concentrations. These findings are consistent with
a previous report of the TNF-α inhibitory effect on insulin
production from INS-1 cells is not attributable to apopto-
sis induction[5]. Furthermore, the reversal in insulin
secretion inhibition by oleic acid is not related to its anti-
apoptotic properties.
Oleic acid does not induce cAMP elevation in INS-1 cells 
treated with TNF-
Fatty acids are capable of binding a number of receptors,
both intracellular and extracellular, making the identifica-
tion of a participating receptor difficult. Recent reports
indicate the involvement of the GPR40 receptor in insulin
secretion augmentation[24,25]. In an effort to achieve
some understanding of the molecular signalling pathway
utilized by oleic acid that results in enhancement in insu-
lin secretion in the presence of TNF-α, we measured the
intracellular second messenger molecule cyclic AMP after
oleic acid treatment. The intracellular cAMP levels in the
TNF-α or oleic acid treatment has no apoptotic inducing effect on INS-1 cells Figure 3
TNF-α or oleic acid treatment has no apoptotic inducing effect on INS-1 cells. Cells were pre-treated with low (1 
μM) and high (10 μM) oleic acid, low (100 pg/mL) and high (1,000 pg/mL) TNF-α or pre-treated for 2 hours with oleic acid (10 
μM) and subsequently treated with TNF-α (100 pg/mL). Twenty-four hours later the apoptotic status of cells was assessed 
using flow cytometry (Annexin V/PI staining). Results are expressed as percent of apoptotic/necrotic cells (upper right and 
lower right quadrant). Shown is one representative experiment performed in duplicate out of three independent experiments.Lipids in Health and Disease 2009, 8:25 http://www.lipidworld.com/content/8/1/25
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presence of oleic acid at concentrations ranging from 10
μM, 5 μM, 1 μM and 0.1 μM in the first 15 minutes did not
change significantly (Fig. 4A). Furthermore, no significant
elevation in cAMP was observed at 30 minutes after oleic
acid treatment 10 μM (data not shown).
Oleic acid induces translocation of PPAR-  in INS-1 cells
Fatty acids and fatty acid metabolites are known activators
of PPAR-γ and have been shown to ameliorate the inflam-
matory effects of TNF-α [26]. Thiazolidinediones (TZDs),
the anti-diabetic class of drugs used extensively for type II
diabetes are also PPAR-γ activators[27]. PPAR-γ transloca-
tion to the nucleus is thought to be mediating the anti-
inflammatory properties of fatty acids. In an effort to elu-
cidate the transcriptional mechanism through which oleic
acid augments secretion of insulin in INS-1 cells, we
focused on the PPAR-γ receptor, a transcription factor that
has the capacity to bind a number of fatty acids and syn-
thetic agonists such as TZDs. The source of PPAR-γ able to
bind peroxisome-proliferator responsive elements
(PPREs) could be both nuclear and cytosolic. We observed
an increase in PPRE binding with oleic acid treatments at
10  μM and 5 μM (Fig. 4B). We also observed a high
increase in PPRE binding in co-treatments with oleic acid
(10 μM) and TNF-α (100 pg/mL). This is suggestive of the
transcriptional role of PPAR-γ in counteracting the inhib-
itory effects of TNF-α.
Peanut oil fatty acid analysis
We then sought to determine levels of oleic acid in the
context of a diet that provides sufficient oleic acid intake
that could yield similar anti-diabetic effects such as those
observed with purified oleic acid. Oils were extracted from
three different brands of peanuts and analyzed for fatty
acid composition (J. Leek Associates, Inc. Albany, GA,
USA). Although the total mono-unsaturated fatty acid
content of the peanut oils was approximately the same,
USDA oil contained much higher oleic acid and much less
linoleic acid (Fig. 5). Another striking difference is the
much higher stearic acid content in USDA oil compared to
other samples. Despite the variations in oleic acid con-
tent, all three brands of peanut are a good source of oleic
acid.
Effect of peanut oil on blood glucose
Based on the fatty acid analysis of the three peanut brands
tested, which revealed a high oleic acid content in all three,
we assessed the impact of peanut oil consumption on fast-
ing blood glucose levels in experimentally induced type I
and II diabetic mice. Once the blood glucose levels reached
15.0 mM or higher, 0.70 mL peanut oil was administered
daily for three weeks. A dosage level of peanut oil for the
mice was chosen based upon studies using dietary oils in
pigs supplemented to 40 g olive or sunflower oil per kg
body weight[28]. Our exploratory study using mice
(A) Oleic acid treatment does not increase intracellular cAMP in INS-1 cells Figure 4
(A) Oleic acid treatment does not increase intracellular cAMP in INS-1 cells. Cells were treated with oleic acid at 
10 μM, 5 μM, 1 μM and 0.1 μM for 15 min. Cellular homogenates were subjected to cAMP assay. Shown is one representative 
experiment with triplicate values out of two independent experiments. No significant difference was observed between con-
trols and treatments. (B) Oleic acid induces translocation of PPAR-γ in INS-1 cells. Cells were treated with oleic acid 
at 10 μM, 5 μM, 1 μM, TNF-α (100 pg/mL) or combination of TNF-α and oleic acid (10 μM) for 18–24 hrs. Nuclear extracts 
were subjected to PPAR-γ detection assay. Shown is one representative experiment with triplicate values out of three inde-
pendent experiments. *, p < 0.05 for cells treated with oleic acid (10 μM) compared to control and combination of TNF-α 
(100 pg) with oleic acid (10 μM) compared to cells treated with TNF-α alone.Lipids in Health and Disease 2009, 8:25 http://www.lipidworld.com/content/8/1/25
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employed 0.70 mL peanut oil, or approximately 18 g oil
per kg body weight per day for three weeks. Clinical studies
demonstrating beneficial effects of peanut butter were
found with a dietary intake of >20 g/day based upon a die-
tary questionnaire with data followed up to 16 years; using
an average body weight of 65 kg, this corresponds to a dos-
age of approximately 0.3 g peanut butter/kg body weight
per day. The blood glucose levels in all type 2 (n = 8) dia-
betic mice, that received peanut oil, was significantly
reduced (8.3 ± 3.7; p = 0.0004 between DM2 and DM2 +
peanut oil; see Fig. 6) whereas no significant changes of
blood glucose (27 ± 6) were observed for type 1 (n = 5) dia-
betic mice that received peanut oil. Fasting blood glucose
levels of both type 1 diabetic (29 ± 4; n = 4) and type 2 dia-
betic (24 ± 10; n = 7) mice that did not receive peanut oil
remained elevated at the end of the 21 day treatment.
Discussion
The present study reveals the anti-diabetic and anti-
inflammatory properties of oleic acid. Oleic acid increases
insulin secretion in the glucose sensitive INS-1 cell line.
Even more noteworthy however, is the ability of oleic acid
to increase insulin secretion in the presence of the inflam-
matory cytokine TNF-α. Previous studies have implicated
TNF-α plasma levels with type II diabetes[29]. The direct
implication of TNF-α levels in diabetes points to the key
role inflammation plays in pathogenesis. Oleic acid treat-
ment was recently shown to influence expression of
approximately 14 genes. These include transcription fac-
tors such as the early response growth factor 1 (EGR1) and
ubiquitin, a protein involved in proteololysis [30].
Fatty acids have been shown to be involved in both pro-
apoptotic and anti-apoptotic pathways[31,32]. Despite
the relatively short duration of oleic acid treatment both
in the presence and absence of TNF-α, we considered the
possibility that the reversal in inhibition was attributable
to an anti-apoptotic effect. Utilizing annexin V and PI, an
assay with an ability to detect apoptosis at the very early
stages of its occurrence, we did not see any appreciable dif-
Fatty acid composition analysis of three peanut oil brands Figure 5
Fatty acid composition analysis of three peanut oil brands. One mL from each of the three oils was extracted twice 
with 1:1 (v/v) chloroform: methanol, 95% ethanol and 2:3 (v/v) ethanol: ether separately. Extracts were evaporated to dryness 
under nitrogen. The extracts were solubilized in 1.0 mL of 5% DMSO in phosphate buffered saline. Analysis was carried out by 
J. Leek Associates, Inc. Albany, GA, USA.Lipids in Health and Disease 2009, 8:25 http://www.lipidworld.com/content/8/1/25
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ferences when compared to controls. The possibility of
oleic acid influencing apoptosis in the long term exists,
however our study focused on the short-term impact.
The specific molecular mechanisms via which unsaturated
fatty acids exert their influence, including oleic acid, are
quite varied. Our findings show that the PPAR-γ receptor
may be involved in the molecular mechanism that
reverses TNF-α insulin inhibition. The detection of PPAR-
γ via interaction with PPREs is suggestive of an increased
availability of this transcription factor at the nuclear level.
The specific promoters or regulatory sequences that are
influenced by the presence PPAR-γ due to oleic acid treat-
ment are not addressed in the present study, but given the
observed outcome, it is evident that it is reversing the neg-
ative impact of TNF-α signalling.
The in vivo system we utilized is based on the KKAy type II
diabetic mouse, which is characterized by high levels of
TNF-α [33]. In this study, consumption of peanut oil,
which is high in oleic acid, was able to reverse the high
glucose levels of all type 2 diabetic mice (8 out of 8) and
normalize values by 21 day treatment of peanut oil,
whereas the blood glucose levels of type 1 diabetic mice
remained unaffected. These findings are consistent with
previous studies that have shown that long term con-
sumption of peanuts and peanut butter lowered the risk
of type 2 diabetes in women[34].
Peanuts are part of the legume family and are rich in
healthy types of fat, and some proteins, fiber, magnesium,
antioxidant vitamin (vitamin E), phytolaxin and resvera-
trol. Both antioxidant and resveratrol could also contrib-
ute to the beneficial effects of peanuts. Resveratrol, one of
the compounds in grapes/red wine thought to be respon-
sible for health benefits, is also present in peanuts but at
lower levels (red wine averages 160 μg of resveratrol/fluid
ounce, compared to peanuts, which average 73 μg per
ounce[35]. In general, peanuts contain various proteins
ranging from 14 kDa to 90 kDa. Among them 62.5 kDa
maturity associated protein, water soluble glycosylated
polypeptides (32.8 kDa and 34.8 kDa) and some lipopro-
tein rich in oleic and linoleic acids are the major protein
components [36-38]. However, based on oil extractions
we carried out and tested, the ingredient responsible for
the observed effect is very likely oleic acid. The peanut oil
analysis shows the striking prevalence of oleic acid in all
brands tested.
The widespread practice of hydrogenation of fatty acids
used in processed foods in the western world including
United States and parts of Europe, is considered to be a
risk factor for a number of diseases. A number of studies
have shown the unique properties of unsaturated fatty
acids and the importance of maintaining the intake of
unsaturated fatty acid as high as possible [39-41]. In a
comprehensive metabolic study Segall et al, showed that
chronic exposure of INS -1 cells, to oleate produced an
increased oxidation and esterification of fatty acids that
might contribute to high basal insulin secretion via
"increased production of reducing equivalents and/or the
generation of complex lipid messenger molecule(s)"[42].
The mechanisms of the anti-diabetogenic action of oleic
acid are very likely multi-faceted. The role of oleic acid in
the presence of the proinflammatory cytokine TNF-α is
clearly beneficial in this study. Dietary supplementation
with MUFAs and PUFAs has been reported to inhibit other
inflammatory cytokines, such as IL-1 and IL-12 [43,44].
Dietary fatty acid intake, particularly unsaturated fatty
acids, may also alter the composition of membrane phos-
pholipids in addition to binding nuclear transcription fac-
tors. Changes in phospholipid composition may in turn
change membrane fluidity thereby altering the binding of
cytokines to their corresponding receptors.
Conclusion
In this study, oleic acid has been shown to increase insulin
production and to reverse the inhibitory insulin effect of
TNF-α. Peanut oil, high in oleic acid, was able to amelio-
rate the diabetic symptoms of type II diabetic mice charac-
Robust decrease of blood glucose level in type type 2, but  not in type 1 diabetic mice following 21 day peanut oil admin- istration Figure 6
Robust decrease of blood glucose level in type type 2, 
but not in type 1 diabetic mice following 21 day pea-
nut oil administration. Kunming mice were injected intra-
peritoneally with 40 mg/kg streptozocin to induce type1 
diabetes. KKAy mice were maintained on a high fat diet for 
10 days to induce type 2 diabetes. Once the mice were char-
acterized to be diabetic, either type I or type II, 0.70 mL of 
peanut oil was administered by gavages to those mice for 21 
days. Control mice were maintained on a standard diet and 
all other mice were maintained on a high fat diet. At the end 
of the experiments the fasting blood glucose levels were 
measured and expressed as mean ± SD (mM glucose) (p = 
0.0004 between DM 2 and DM 2 + P. Oil; p = 0.0003 
between control and DM 2 and p = 0.05 between control 
and DM 1).Lipids in Health and Disease 2009, 8:25 http://www.lipidworld.com/content/8/1/25
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terized by inflammation. The findings are consistent with
earlier clinical and epidemiological findings that peanuts
are beneficial in lowering the risk of type 2 diabetes in
women. This study provides further evidence to the
importance of regulating inflammation using naturally
occurring molecules found in certain foods. Furthermore,
it indicates the importance of unsaturated fatty acids and
their potential to regulate inflammation.
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